Pages

Thursday, June 23, 2011

兒童用潛降型輪椅!!

醫療展豋場 減重行動家上線  2011/6/24【記者張雅雯台北報導】「二○一一台灣國際健康暨醫療展覽會」與「銀髮族暨健康照護產業展」,昨起在世貿一館豋場,工研院醫療器材快速試劑服務中心展示最新的成果,負責人蔡秀娟表示,這個平台接受臨床醫師的提案構想,研發出可行且符合安規的原型機,再由產業量產。手術輔助升降台就是一例,蔡秀娟指出,以往進行腹腔鏡手術時,醫師若要調整手術高度,不是搬椅子、就是視情形調整手術檯,這種「人因工程」往往耗費時間且影響流暢度,研發出升降台透過踩踏,就能讓主刀醫師與第一助手調整高度。輔具也是這次展覽的重頭戲,鞋類暨運動休閒科技研發中心展出多款「名車」,包括可協助輪椅使用者站立、傾躺的「人因站躺姿態變換系統」;或是讓下肢不便孩童可方便從地面起身的「兒童用潛降型輪椅」,除了可前後行動,還可調整高度介於二十至七十公分,參觀者甚至以熱門電影《變形金剛》加以形容。減重是各年齡層都關心的話題,工研院本月將「減重行動家」軟體上線,科技整合與創新服務部經理張振魁表示,透過與智慧型手機結合,民眾免費下載後可擬定減重計畫,隨時透過手機拍攝每天的飲食、點選做了哪些運動,這套系統未來也可望與減重班合作,學員可即時上傳飲食的照片,讓營養師檢視熱量、及時提供諮詢。展期至二十六日,「銀髮族暨健康照護產業展」四天皆免費入場,「國際健康暨醫療展覽會」只有周六、日才免費開放給民眾。

健保局增Cyclosporine用於乾眼症規定

行政院衛生署中央健康保險局 令 發布日期:100.06.22   健保審字第1000004376  修正「全民健康保險藥品給付規定—第14 眼科製劑 Ophthalmic preparations 14.9.3 Cyclosporine (Restasis)」部分給付規定,並自中華民國一百年八月一日生效。附修正「全民健康保險藥品給付規定—第14 眼科製劑 Ophthalmic preparations 14.9.3 Cyclosporine (如Restasis)」給付規定

 

 

「全民健康保險藥品給付規定」修正規定

14 眼科製劑 Ophthalmic preparations

(自1008 1日生效)

修正後給付規定

原給付規定

14.9. 其他 Miscellaneous

14.9.3 Cyclosporine (Restasis)  (100/08/1)

限符合下列條件,乾眼症嚴重程度為Level 4之病患使用:

1.嚴重乾眼症〔淚液分泌測試     Schirmer's test without anesthsia)少於2mm/5min〕,需附檢查試紙。

2.淚膜崩裂時間(Tear Film Break-Up Time)為immediate

3.螢光染色之照片,顯示有嚴重角膜點狀上皮缺損,結膜充血染色且有絲狀角膜炎,角膜潰瘍,或眼瞼結膜粘連,角膜結膜角質化之情形。

4.曾使用局部抗發炎藥物或淚點塞未見改善。

5.視力功能檢查結果<0.6

6.須經事前審查核准後使用,六個月審查一次,若未改善則需停藥。

 

14.9. 其他 Miscellaneous

14.9.3

 

備註:劃線部份為新修訂之規定。

佳醫佈局長期照護!!

ABH明年上興櫃,佳醫轉投資進入收割期2011-06-23 【時報】佳醫集團轉(4104)投資進入收割期,與大陸國藥合資的「御佳醫療」的第一家醫療通路最快年底前將在北京成立,合資成立的五官醫院納入醫保後也轉盈,專攻銀髮醫療照護商機的Aisa Best HealthcareABH),增資後佳醫將持股30.78%,去年開始獲利,今年目標要達3千床,預計明年第一季底登錄興櫃,成佳醫集團的另一隻金雞母。長期照護商機龐大,內政部調查,台灣截至99年底,超過65歲的老年人口近250萬人,年增率約10.74%。據統計,全球老年人口將從2011年起到2029年邁入高峰期,2017年台灣超過65歲的老年人口達14%、2025年更達20%,台灣老年化的速度十分驚人。除了轉投資ABH,佳醫也評估成立銀髮村搶長照商機。日本業者看好商機,近日也傳出日商Uchiyama來台尋求與佳醫合作,欲搶攻台灣老年人口照護市場。ABH由佳醫、龍巖(5530)和華威創投等合資成立,日前增資到6,861萬美元(約新台幣20億元),佳醫持股30.78%,龍嚴持股近2成。目前ABH1,300個床位,希望透過併購方式,年底前增至3千床,不過,礙於價格問題,市場評估,年底前應可達2千床。除台灣市場,ABH也評估進軍東南亞市場,如馬來西亞等,及中國大陸市場。御佳醫療由佳醫與中國國藥合資成立,額定資本額為5億人民幣,目前實收資本額為2億人民幣,佳醫持股49%。第一家醫療通路將設在北京,已拿到公司許可,預計7月拿到各項營業執照,最快年底正式開業,將設立醫美及眼、牙、皮膚科等,醫美部分將結合曜亞(4138)的資源,共同搶進大陸龐大商機。未來雙方將陸續在上海、瀋陽、天津、杭州、福建、廣州等地開設據點,爭取醫改商機。

探究移動醫療產業 中國移動醫療產業大會將召開

20110623  信息通信技術對我們生活的改變,已經從"溝通無處不在"逐漸走向"溝通無所不能",移動醫療就是明證。移動醫療,顧名思義就是可以移動的醫療服務,國際醫療衛生會員組織HIMSS給它的定義為,mHealth,就是通過使用移動通信技術——例如PDA、移動電話和衛星通信來提供醫療服務和信息。這種醫療手段不僅能夠很好的解決醫療人力資源短缺的問題,更為很多突發疾病提供了及時的救治手段,讓醫療服務"隨手可得"。

移動醫療"衝破傳統醫療痼疾 在信息化快速發展的今天,傳統醫療模式的局限性日益凸顯。在我國,由于地區差異造成醫療資源不均衡,不發達地區資源短缺,"看病難、看病貴"已成為困擾醫療行業的頑疾。在這樣的背景下,移動醫療行業順勢而出。中國工程院秘書長鄔賀銓曾在一次業內會議上勾勒出了數字醫療未來的發展方向:移動通信覆蓋的人群日益增多,2012年全球將有半數人使用手機,數字衛生就是要把許多醫療信息,直接傳送到手機上,帶著手機就能看病。這樣的醫療模式對中國醫療改革具有更重要的意義,不僅可以緩解群眾看病難的問題、減輕醫院門診壓力,還可以提升社會人口素質,為政府減少"未富先老"帶來的壓力。同時,基于信息化基礎的移動醫療可以拓寬信息產業的覆蓋范圍,更好的服務社會。目前,移動醫療在部分典型應用的推廣效果比較好,但是仍處于起步階段,在與國內現有醫療衛生係統協同的進一步緊密結合上,還面臨諸多困難。在建設方面,需要依靠政府、醫院、移動運營商、廠商形成多方"合力",將更多醫療行業信息化應用植入其中,推動移動醫療的快速發展。

產業各參與方覬覦待採金礦 對于電信運營商、醫療設備商、芯片企業、軟件商、係統方案商等產業鏈上遊參與者而言,移動醫療無疑還是一座尚待發掘的"金礦"。據市場咨詢機構預測,全球移動醫療市場規模達到數十億美元。然而,移動醫療產業在國內剛剛興起,跨界融合了信息通信和衛生醫療兩大產業,產業鏈周邊涉及面廣,帶動的市場規模不可小覷,也將直接推動兩大產業的融合發展,並帶動產業鏈上的電信運營商、設備商、終端商、係統集成商、軟件方案商等眾多參與者的發展,從而惠及整個產業。由中國通信學會主辦的"2011中國移動醫療產業大會"定于812在北京國賓酒店隆重召開。大會從開始籌備以來就受到了廣泛關注,眾多業界人士致電咨詢、踴躍報名。作為國內首個且唯一關注移動醫療產業的專題活動,得到了兩大主管部委的指導支持,有關分管領導將出席大會;中國工程院、中國科學院權威院士專家將蒞臨做重要發言,把脈移動醫療產業;而作為醫療信息化主力軍的電信運營商,將從集團公司戰略到地方運營實踐全面參與;同時組委會還將著力邀全國重點醫院、預防保健機構的的IT負責人的廣泛參與,也歡迎醫療行業相關負責人咨詢報名;在媒體方面,大會得到了諸多行業知名媒體的關注和報道,並邀請門戶網站和行業門戶對大會現場直播和微博互動。

 

太平洋證券 對永信全球佈局的看法!

永信在與日商合作進軍日本市場,給予20~25X的本益比 2011/06/23 (太平洋證券 提供) 投資建議與結論 1.投資建議 買進 2.結論 永信在與日商合作進軍日本市場,以及受惠日本政府欲將學名藥提升至三成之醫改政策,預期永信儼然為此波政策下之主要受惠者,加上目前除日本合作題材外,公司美國、中國、東南亞市場轉投資部份投資收益預期將日益顯現,目前本益比約20X左右,給予20~25X的本益比,建議買進。3.訪談內容:

台廠最大的學名藥廠 永信為台灣規模最大的學名藥藥廠,其生產藥品品項結構以人體用藥為主佔約七成以上,其餘則以少部份動物藥品、保健食品、以及代工產品為主。公司佈局以神經系統藥物、循環系統藥物、呼吸系統藥物、消化系統藥物、代謝作用藥物、泌尿生殖系統藥物、抗微生物藥物及皮膚外用藥等多元化方向發展。

永信將以Co-branding形式切入日本市場 永信於日本佈局許久,受限於日本市場民族性較為封閉,日本醫療院所皆以其當地藥商及供應商為主要首選,加上日本用藥習慣仍以專利藥以及原廠藥品為主,因此日本市場一直為國內與國外廠商難以切入之市場。鑒於日本市場以往之經驗,永信改變策略模式選擇以日本當地藥廠合作,以Co-branding共同品牌的觀念形式切入日本當地市場,永信與日廠WAKAMOTO於日前共同簽署MOU,其內容為雙方合資於日本當地成立一學名藥公司,以共同品牌模式於日本當地銷售,並以雙方之優勢互補合作搶食市場。目前永信與WAKAMOTO合作進度僅於備忘錄的簽訂協商階段,相關細項股權、持股比例等皆在商談中,未來藥品品項將以醫院急、重症用藥為發展重點,相關劑型則以針劑與錠劑之處方藥為主,合作初期將以市場上快到期之專利藥為其爭取學明藥業務,並不排除同時計畫以併購日本當地其他藥廠之藥證等方式為初期營運方式,預期合資成立之公司3年內將送25~30張藥證的申請,預期永信在與日本當地老字號藥廠WAKAMOTO合作進攻日本藥品市場策略下,日本市場貢獻可期,然短期內仍處於佈建初期未能有任何營收貢獻,預期最快2013(併購當地藥證收益為主)方可對永信有獲利貢獻挹注。

美國為永信發展速度較快且穩定成長之市場 美國佈局部分(YSP USA),產品多為止痛、消炎藥品為主,由於公司看好美國地區民眾對學名藥的接受度比較高,因此永信以自有品牌Carslbad與當地通路商WalGreenCVS,經銷商MckesoonMaster RX等大、小通路、經銷商合作外,其合作模式尚有替Watson代工學名藥業務,目前美國地區共有十餘張的藥證,其產品以消炎、止痛、降血脂、抗生素等為主,但由於市場尚未完全打開,因此僅約4~5種銷售狀況比較好,且於美國自有品牌Carslbad的部份,為提升市場知名度以及市佔率,壓低售價價格犧牲部分產品利潤,去年美國部分貢獻永信營收約3.31億元。展望今年預期美國子公司CTI可望有兩成左右的成長空間,其主要成長動能來自於CTI於近期取得美國軍方鎮熱解痛約五年左右的標案,二為永信於當地已販售之藥品中,其一項藥品因競爭對手未通過FDA查廠許可,永信可望因此而提升此藥品在當地美國市場的市佔率,而新產品方面預估今年將再增加1~2個品項,然雖美國子公司獲利貢獻在知名度尚未打開,以及剩餘之藥證市場尚未打開前難有大幅度獲利貢獻,但短期內因獲新標案與競爭對手失利等因素的帶動下,以及Carslbad與當地經銷商與通路商合下今年仍可望穩定成長。

預期明年起多角化佈局之大陸市場將步入收割期 永信於大陸市場(YSP International Company Limited)之佈局方向以三類新藥為主,其中包括負責生產與銷售大陸市場西藥及成藥的昆山永信藥品、醫藥原料進出口貿易的上海永日藥品、化學合成醫藥品研發及成果轉讓授權的江蘇德芳醫藥、位於上海負責保健食品業務的佑康貿易等、進出口人用及動物用藥品的香港永信等。除原有之佈局外,永信於去年展開與美商之合作案雛形也逐漸成型,其案為永信轉投資之子公司永日、永信與美商BRI三方合資於中國湖北成立的永瑞生物科技公司,永日與永信持股約六成480萬美元(總投資額800萬美元),其生產之產品以VersazymeSSG兩大類產品為主,Versazyme為美商BRI飼料添加劑之專利產品,功能為增加肉雞體重和促進飼料轉化率功能,與分解Prion狂牛病的致病蛋白質,其廠房與生產線相關設備可望於明年底建置完畢,初期總產能將為1,000/年,預期此部分最快於明年底開始出貨,且預估此產品於中國市場約有1.6億美金的市場,加上此部分之產能可望在2016年擴增至8,000噸的年產能下,預期此部分可望為永信明後年成長動能之主要來源之一。此外,除與外商合資之投資案外,未來永信也計畫在今明兩年與中國當地廠商合作聯盟,亦或是明後年藉由併購當地藥廠進一步壯大中國市場通路,因此中國市場方面,預期明後年將為永信佈局的重要收割期。

東南亞佈局成果日益顯現 在東南亞佈局方面(YSP OVERSEA),因東南亞地區行銷總公司因馬來西亞當地醫藥相關法規、制度、法治等相較其他東南亞國家完整,因此永信於當地設立GMP藥廠生產並外銷至東南亞地區,在馬來西亞銷售通路主要以當地診所與藥局為主,新加坡也有約5,000家左右的通路,永信東南亞並於馬來西亞當地掛牌上市,目前年營業額為1.3億元馬幣(13NTD),稅後淨利約1億元左右,約貢獻永信4,000萬元/年,今年Q1約認列1,300萬元(NTD),未來公司計畫將永信東南亞回台發行TDR,其生產廠銷售國家除馬來西亞外尚有新加坡與汶萊,另外公司去年於越南籌畫成立動物用藥廠,已於今年四月開始投產,其產能除供應當地外尚會供應給其他東南亞地區之國家,因此預期此部分獲利貢獻效益將日益浮現。

2011年國內市場在本業穩定向上及開發階段的保健食品下僅小幅成長 永信藥品的產品線佈局多元化,大部分學名藥以銷售至國內診所以及藥局的內銷市場為主,但由於國內藥品市場在使用專利藥風氣盛行,以及健保局近年來不斷針對市面上共7,000多效藥品進行砍價的效應下,公司選擇切入相對毛較高的健康食品、醫學美容產品,並以多品牌策略及訴求健康與美麗的形象,以 HAC Carslbad的品牌切入此市場,產品佈局的方式則以進入國內連鎖藥粧〈康是美、屈臣氏〉以及便利商店〈7-11/全家/OK〉等通路銷售至終端消費者。此外,並於大甲以及豐原等地設置HAC品牌的實體通路店,惟目前保健食品以及醫美市場仍在初階的建佈期,佔整體營收比重仍少於一成以下,營收貢獻截至今年Q3僅約2億元,預估全年2.8億左右,年成長率不到4%,實質貢獻仍低,預估2011年在國內有限的學名藥市場以及開發階段的保健食品貢獻效應尚未顯現下,公司本業部份整體營收34.86億元,僅較去年小幅成長4.52%。*本公司提供之資料力求準確無誤,但本公司對其全部或任何部分內容的準確性或完整性不承擔任何責任。客戶在進行買賣時,請自行判斷。如因此產生任何損失,概與本公司無關。

Lancet reports on Facebook use in Taiwan health-care reform

2011/06/23 Taipei, June 23 (CNA) The prestigious medical journal The Lancet has published an article in its latest issue detailing how Facebook has enabled collaboration between stakeholders in emergency medicine policy in Taiwan, which has led to reforms. The article was contributed by Li Yu-chuan, dean of Taipei Medical University's College of Medical Science and Technology, who headed the study on using social networking services to transform the delivery of health care. Li said Thursday that due to a lack of knowledge of emergency room functions, many local people often rush there when they feel sick, a habit that leads to overcrowding in emergency rooms and creates trouble for first-line medical staff. Over the past few years, he went on, the Taiwan Society of Emergency Medicine has seen slow progress in negotiations with the Cabinet-level Department of Health (DOH) for an appropriate solution to emergency room overcrowding. A breakthrough was achieved in February this year, though, when an emergency physician who is an active social network user created a Facebook group called "Rescue the Emergency Room," Li said. Within a week, about 1,500 people, most of whom are emergency room staff at medical institutions around Taiwan, had become members of the group, Li said, adding that even President Ma Ying-jeou and Department of Health Minister Chiu Wen-ta joined. "By March 11, there were about 1,800 members, 455 posts and 3,745 comments and `likes' on these posts," Li wrote in The Lancet article, adding that the number of members and posts is increasing every hour. After monitoring the discussions on Facebook, Li said, Chiu and his team decided to make a surprise visit to emergency departments in 10 different cities around Taiwan. Afterwards, Chiu promised in a press release "to initiate dialogue with the DOH's Bureau of National Health Insurance on organizational issues affecting emergency departments and vowed to allocate more resources for hospitals to improve emergency room overcrowding and quality of care," Li said in the article. Noting that the case has implications for the future of health care, Li said it shows how social networking can break down the rigid social and professional hierarchical structures that can hinder reform. With Facebook emerging as a prevailing social networking tool, Li said, it can help connect the government, hospitals and emergency room medical staff to improve the delivery of health care and strengthen communication with patients. (By Hsu Chih-wei and Sofia Wu) ENDITEM/J

基亞PI88 肝癌臨床三期進度追蹤…

PI-88 Phase III Update  Brisbane, Australia, 23rd June 2011. Progen Pharmaceuticals Ltd (ASX:PGL, OTC:PGLA) today provide the following update on PI-88 licensee progress with moving into pivotal Phase III clinical trials in liver cancer. Medigen Biotechnology Corporation (MBC) licensed PI-88 from Progen on an exclusive worldwide basis for oncology indications in June 2010. MBC will undertake a prospective randomised, double blinded, placebo controlled, parallel group, international, multicentre, Phase III trial of PI-88 in the adjuvant treatment of subjects with hepatitis virus-related hepatocellular carcinoma (HCC) after surgical resection which will be known as the PATRON trial. As previously announced (19th April 2011), the PATRON trial is already approved to proceed in Taiwan by the Taiwanese Food and Drug Administration. MBC has since completed the Taiwan Investigator meeting with more than 20 trial investigators participating. MBC has also submitted the PATRON protocol to both the Korean and Chinese regulatory authorities for review. Further, MBC informed Progen that the European Medicines Agency's Committee for Orphan Medicinal Products has positively reviewed the application for PI-88 to receive Orphan Medicinal Product Designation for the treatment of HCC. Progen's contract manufacturing subsidiary, PharmaSynth Pty Ltd, has manufactured and coordinated the preparation of the clinical trial drug supplies. These have been sent to MBC's Clinical Research Organisation for distribution to the clinical trial sites in readiness for the enrolment of the first cohort of patients. As MBC continues to make progress developing PI-88, Progen benefits through milestone payments and contract manufacturing services provided by PharmaSynth. The next milestone payment is payable when the first patient is treated, which is expected to occur during Q3 2011. ENDS About Progen Pharmaceuticals Ltd Progen Pharmaceuticals Limited is a biotechnology company committed to the discovery, development and commercialization of small molecule pharmaceuticals primarily for the treatment of cancer. Progen has built a focus and strength in anti-cancer drug discovery and development. www.progen-pharma.com For more information: Sue MacLeman Chief Executive Officer +61 7 3842 3325 +61 437 211 200 This release contains forward-looking statements that are based on current management expectations. These statements may differ materially from actual future events or results due to certain risks and uncertainties, including without limitation, risks associated with drug development and manufacture, risks inherent in the extensive regulatory approval process mandated by, amongst others, the United States Food and Drug Administration and the Australian Therapeutic Goods Administration, delays in obtaining the necessary approvals for clinical testing, patient recruitment, delays in the conduct of clinical trials, market acceptance of PI-88, PG11047, PG545, PG562, PG11122, PG11144 and other drugs, future capital needs, whether or not EPI can be funded or divested successfully, general economic conditions, and other risks and uncertainties detailed from time to time in the Company's filings with the Australian Securities Exchange and the United States Securities and Exchange Commission. Moreover, there can be no assurance that others will not independently develop similar products or processes or design around patents owned or licensed by the Company, or that patents owned or licensed by the Company will provide meaningful protection or competitive advantages

友華生技 開始一線癌症免疫療法Multikine三期試驗

CEL-SCI Announces Start of Multikine Phase III Study by Orient Europharma in Taiwan 2011/06/23 Source:biowire CEL-SCI Corporation (NYSE AMEX: CVM) announced today that its Taiwanese partner, Orient Europharma, has concluded the Site Initiation Visit for the first Taiwanese clinical center in CEL-SCI's Phase III clinical trial for Multikine®, the Company's flagship cancer immunotherapy. The first center is called Shin Kong Wu Ho-Su Memorial Hospital and is located in Taipei, Taiwan. The Site Initiation Visit is the final step before patient enrollment begins. The Multikine to be used in the study is being delivered this week to Taiwan, and patient enrollment is expected to start soon. Orient Europharma plans to sign up another 6 Taiwanese clinical centers to conduct this study, which is already ongoing at multiple clinical sites in the United States, Canada, Poland, Hungary and India. The total study is expected to enroll about 880 head and neck cancer patients in over 40 hospitals in 9 countries. CEL-SCI's partner Teva Pharmaceuticals will conduct parts of the Phase III study in Israel. Geert Kersten, CEO of CEL-SCI said, "Taiwan has a large number of head and neck cancer cases due to the widespread use of betel nut, along with alcohol and smoking, which are common causes of head and neck cancer. We expect Taiwan to rapidly accelerate our overall patient enrollment as head and neck cancer represents a large unmet medical need in the country." The goal of this study is to establish Multikine as a first-line standard of care therapy in treating newly diagnosed head and neck cancer patients. The trial is believed to be the largest head and neck cancer study ever conducted and is called "IT-MATTERS", an acronym for: Immunotherapy Multikine Anti Tumor Treatments. CEL-SCI's Phase III clinical trial is an open-label, randomized, controlled, multi-center study designed to determine if Multikine administered prior to current standard of care (Surgery plus Radiotherapy or Surgery plus Concurrent Radiochemotherapy) used for treatment of naive subjects with Advanced Primary Squamous Cell Carcinoma of the Oral Cavity/Soft Palate (Head and Neck cancer) will result in an increased overall rate of survival versus the subjects treated with standard of care only. It will also be the first trial in which immunotherapy will be administered before any other traditional means of care are attempted. A detailed description of the study can be found at http://www.clinicaltrials.gov/ct2/show/NCT01265849?term=multikine&rank=1. Phase II clinical trials of Multikine demonstrated the product was safe and well-tolerated and eliminated tumors in 12% of the subjects less than a month into treatment. The Multikine treatment regimen was also shown to kill, on average, about half of the cancer cells in the subjects' tumors before the start of standard therapy. Follow-up studies of subjects enrolled in the "proof of concept" Phase II trial showed a 33% improvement in the survival rate of those treated with Multikine at a median of three and a half years following surgery. The U.S. Food and Drug Administration granted orphan drug status to Multikine in the neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck.

About CEL-SCI Corporation CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine. CEL-SCI is also developing an immunotherapy (LEAPS-H1N1-DC) to treat H1N1 hospitalized patients and a vaccine (CEL-2000) for Rheumatoid Arthritis using its LEAPS technology platform. The LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu as CEL-SCI scientists are very concerned about the creation of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.  For more information, please visit www.cel-sci.com. When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended September 30, 2010. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

國際醫療專區能容許更多的聲音嗎??

醫院公司化 利專業與商業拉鋸 2011/06/24 經濟日報】 2011.06.24 「我希望你稱呼我為張醫師,而非稱我張董事長」。基亞生技公司董事長張世忠創業至今已12年,他的公司在生技產業界已經創下不小成就,但張世忠永遠無法忘懷,當初辭去慈濟大學醫學系主任時,來自外部同儕壓力與自己內心的掙扎。 台大醫學系畢業的張世忠,36歲被證嚴法師送到英國攻讀醫學博士,四年後回台接掌慈濟醫學系系主任,成為國內醫界相當耀眼的明星,但他選擇45歲時轉戰生技產業。 張世忠永遠無法忘記,花蓮地方報紙以斗大標題寫著,「張世忠要棄醫從商」,這四個字,至今在他心裡仍感到刺痛。離開慈濟前,張世忠懇請與證嚴法師單獨談了三小時,直到獲得證嚴法師的祝福,他的心緒才逐漸平靜。 張世忠說,進入台大醫學系的第一天,他認定自己已進入全台最高知識殿堂,這一切追求真理而努力打拼,是為了濟世救人這種崇高理想。

醫商並存 價值觀激烈衝撞 「如果我只想要賺大錢,並不需要當醫生,」張世忠這一句話,道盡了全世界所有醫生的基本信念。 所有醫學院畢業生,永遠要記得希波克拉底的誓言「我將不容許有任何宗教,國籍,種族,政見或地位的考慮介於我的職責和病人間。」在希波克拉底的精神下,醫生這一行業絕不能以營利為目的。 但是自98年底開始,在總統府財經小組的共識決策下,政府終於決定推動醫院得以公司化,開啟這一扇窗的,正是國際醫療專區。 衛生署醫事處處長石崇良解釋,為了創造台灣的國際醫療產業,應該允許醫院可以透過股票的公開籌資,以足夠的資金進行大規模的建設。 但是石崇良也坦承,要推動國際醫療的挑戰很大,他舉例,全台醫療人員約有30萬人,他們要如何說服其餘2,000萬人,應該把醫療當產業來推動? 初聽到衛生署將修法讓醫院可以公司化時,民間督保聯盟秘書長滕西華當下直呼「不可思議」,她認為醫療和教育,原本應被列入憲法保障為公共財,政府應全力保障讓民眾不受任何差別待遇,怎麼可以帶頭讓醫院走向資本化? 民進黨立委黃淑英聽到政府將透過醫療專區,允許國際醫院得以公司化,楊淑英第一個反應是,怎麼可能真正成功的區隔。

未達共識 醫療階級恐對立 黃淑英反問,台北市忠孝東路上有很多醫美診所,擺明了都是營利為目的,政府又如何限制這些診所在國際醫療專區外不可以資本化。黃淑英說,整個社會價值觀,對於醫院的公司化尚未達成共識,貿然實施醫院公司化,只會造成醫療階級的對立。和信醫院院長黃達夫更是直切反對,讓醫院走向資本化絕對是荒謬的,醫生和病人之間存在高度的知識的不對等,當一名醫生告訴病人,你需花多少金錢來治療,多數病人無從判斷醫生的建議是基於人道與專業,還是基於商業目的。然而,長年推動醫院公司化的時代基金會執行徐曉波指出,醫生固然不應以營利為目的,但是憲法,卻應該保障醫生以營利為目的的自由。當民眾將其最基本的生命存續交付給醫院來服務時,能否容許商業化的力量介入,對台灣多數人來說仍然是個持續思考的議題。

專家看資本化 異見多 

中研院院士,台大醫學院特聘講座教授陳定信:如果把醫療當事業,雖然對傳統價值觀造成衝突,但外國人也是人,如何避免醫療資源分配不均,確保民眾都能被照顧才是重點。

長庚體系最高顧問吳德朗:國際醫療專區規劃的醫院病床數太少,不足以吸引長庚投入,醫院能否公司化的問題,我們以非營利模式一樣可賺到錢,賺到的錢全部投入醫院病人的服務品質。

中國醫藥大學董事長蔡長海:支持國際醫療專區及醫院公司化,中國醫藥大學也有興趣爭取。

國光生技董事長詹啟賢:醫院公司化雖然有違傳統醫療價值,但是台灣應該允許不同的價值觀存在

台大健康政策與管理研究所教授江東亮:醫院能否公司化的課題,就像台灣應該朝資本主義或社會主義的路線去發展一樣,是一個很難有結論的問題。

新光醫院院長侯勝茂:推動國際醫療是醫界共同心聲,但規劃設立國際醫療專區的必要性則值得討論。境外人士有時自海外慕名來台,卻發現醫術高超的名醫不見得在國際醫療專區內看診,所以建議在現有的大型醫學中心旁,也開放新設國際醫院,成功機會將更大。

慈濟大學公衛系教授葉金川:國際醫療的公司型態以營利為目的,中下階層完全感受不到這個制度的好處,獲利的將是財團。

訊映雲端血糖追蹤儀!!

訊映血糖追蹤儀 雲端運用2011-06-24 工商時報  訊映光電副總張德全表示,除了歐克葡萄試驗系統外,不段創新研發,推出血糖醫療追蹤儀,多樣產品陸續上市,業績倍數成長,預計股票明年第1季上櫃。興櫃醫療生技股訊映光電(4155),專業於生物感應技術相關之檢測儀器和檢測試片如血糖儀、血糖試片等。去年營收4.1億元,稅後淨利3,773萬,EPS2.71元。受惠於景氣回升,加上經營「歐克」品牌有成,預計於今年8月送件申請上櫃,明年Q1有機會正式掛牌。 訊映光電副總經理張德全表示,公司雖成立時間不長,但以「服務、彈性、成本、品質及創新」等特質,默默耕耘血糖機市場。雖然血糖機市場競爭者眾多,但透過努力追求品質的精神,逐步跟上國內外知名血糖機大廠的腳步,已成功開發具世界水準的血糖儀、血糖試片,產品通過美國FDA、歐洲ISO 13485CECMDCAS、台灣GMP等認證,並取得多項多國專利。產品已受到世界各國認同,無論在準確度及成本控制上,均嚴格管理,讓該公司營業額保持穩健成長,未來將持續自我突破,維持與客戶良好的關係鏈,將公司能量發揮至極限。 隨著人口老化加快,醫療將成為未來最紅火的產業。訊映公司為一家不斷追求進步的公司,透過生物科技技術、光電技術及能源科技的應用,稟持服務人群的觀念經營企業,以自有品牌進入市場,今年推出雲端遠距照顧血糖醫療追蹤儀產品上市,雲端應用,單鍵操作容易,短期內成為台灣、大陸市場的領導品牌,追求完美,師法國際大廠,提供優質且滿足客戶需求的高科技產品,並推進國際市場,接受OEMODM以吸納更多客戶,掌握全球市場先機,提升人類生活品質。